Sobi to acquire CTI BioPharma

Thursday 11 May 2023


Swedish Orphan Biovitrum AB (Sobi) is to pay $1.7 billion to acquire a company that will expand its presence in drugs for rare haematological diseases. It is the Swedish company’s biggest deal to date. The target company is CTI BioPharma Corp of Seattle, US which has a recently approved product for adult patients with myelofibrosis and thrombocytopenia, a condition that occurs when the platelet count in the blood is too low.